$39.28
▼ -0.6% Today
as of Jul 22, 09:05 ET
Last 30 days
Recent Press Releases & News
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Overview
52-week range
$14
$36
100% of range
Avg surprise (last 3)
+0.8%
Avg reaction (last 2)
+20.4%
100% positive
Latest IV / EM
83%
EM ±19.3% · $40 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 20, 2026 | Mar/2026 | $-0.73 | $-0.60 | -21.7% | -14.1% | +35.3% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.61 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.73 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.60 | $-0.69 | +13.0% | — | — | earnings |
| Thu May 29, 2025 | Mar/2025 | $-0.64 | $-0.72 | +11.1% | — | +5.6% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-0.76 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-0.74 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.60 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.36 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.45 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.57 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.66 | -$0.60 | -10.0% |
Financials
Income statement (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $-111M | $-127M | $-121M | — | $-111M | $-109M | $-87M | — |
| EPS (diluted) | $-0.61 | $-0.73 | $-0.71 | — | $-0.76 | $-0.74 | $-0.60 | — |
Balance sheet (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $995M | $522M | $599M | $714M | $375M | $473M | $560M | $635M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.04B | $574M | $652M | $768M | $413M | $507M | $589M | $666M |
| Total assets | $1.05B | $583M | $661M | $776M | $421M | $516M | $590M | $666M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $66M | $63M | $53M | $69M | $68M | $67M | $45M | $49M |
| Total equity | $986M | $520M | $609M | $707M | $353M | $449M | $545M | $618M |